Blueprint Medicines Corp (BPMC) Stock Price, Quote & News

Latest News on BPMC

Apr 7, 2025, 5:37 AM EDT - 13 days ago

Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth

Mar 31, 2025, 8:00 AM EDT - 20 days ago

Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

Feb 28, 2025, 8:00 AM EST - 7 weeks ago

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

Feb 13, 2025, 11:32 AM EST - 2 months ago

Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 7:00 AM EST - 2 months ago

Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results

Feb 5, 2025, 8:00 AM EST - 2 months ago

Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Jan 12, 2025, 4:00 PM EST - 3 months ago

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth

Dec 18, 2024, 8:00 AM EST - 4 months ago

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 7, 2024, 12:30 PM EST - 4 months ago

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting

Nov 15, 2024, 5:26 PM EST - 5 months ago

Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs

Nov 14, 2024, 3:18 PM EST - 5 months ago

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

Oct 30, 2024, 2:29 PM EDT - 6 months ago

Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:00 AM EDT - 6 months ago

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Oct 16, 2024, 8:00 AM EDT - 6 months ago

Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Sep 11, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Has Launched An Inquiry Into Whether Blueprint Medicines Corporation Violated Securities Laws And Impacted Investors Are Invited To Join

Sep 10, 2024, 11:00 AM EDT - 7 months ago

Blueprint Medicines Corporation Is Being Investigated For Securities Fraud And Stakeholders With Losses Should Contact The Schall Law Firm

Sep 10, 2024, 8:00 AM EDT - 7 months ago

Blueprint Medicines to Present at Upcoming Investor Conferences

$The Schall Law Firm Invites Investors To Join An Inquiry Into Blueprint Medicines Corporation For Possibly Committing Securities Related Infractions$

Sep 9, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Invites Investors To Join An Inquiry Into Blueprint Medicines Corporation For Possibly Committing Securities Related Infractions

Sep 7, 2024, 11:00 AM EDT - 8 months ago

Blueprint Medicines Corporation May Have Engaged In Securities Fraud And Shareholder Participation In An Investigation Is Encouraged By The Schall Law Firm

Sep 5, 2024, 11:00 AM EDT - 8 months ago

Blueprint Medicines Corporation May Have Defrauded Shareholders And The Schall Law Firm Wants Those With Losses To Reach Out

Sep 3, 2024, 11:00 AM EDT - 8 months ago

Blueprint Medicines Corporation May Have Defrauded The Public And The Schall Law Firm Seeks Shareholder Participation In An Inquiry

Sep 2, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Is Looking Into Whether Blueprint Medicines Corporation Committed Securities Related Improprieties And Investors Should Reach Out

$Shareholders Can Now Join The Schall Law Firm In Investigating Securities Related Infractions By Blueprint Medicines Corporation$

Sep 1, 2024, 11:00 AM EDT - 8 months ago

Shareholders Can Now Join The Schall Law Firm In Investigating Securities Related Infractions By Blueprint Medicines Corporation

Aug 31, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Is Looking Into Blueprint Medicines Corporation's Possible Securities Fraud And Investors Are Invited To Assist

Aug 30, 2024, 11:00 AM EDT - 8 months ago

Blueprint Medicines Corporation May Have Violated Securities Regulations And The Schall Law Firm Seeks Shareholders' Help In The Inquiry

Aug 29, 2024, 11:00 AM EDT - 8 months ago

Investors Are Encouraged To Contact The Schall Law Firm About An Investigation Into Blueprint Medicines Corporation's Securities Related Impropriety

Aug 28, 2024, 11:00 AM EDT - 8 months ago

Blueprint Medicines Corporation May Have Committed Securities Fraud And The Schall Law Firm Seeks Shareholders To Join An Inquiry

Aug 26, 2024, 11:00 AM EDT - 8 months ago

Blueprint Medicines Corporation Is Being Looked Into For Possible Securities Fraud And The Schall Law Firm Invites Shareholders To Help

Aug 24, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Is Investigating Blueprint Medicines Corporation For Securities Fraud And Stockholders With Losses Are Invited To Contribute

Aug 22, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Encourages Stockholders With Losses In Blueprint Medicines Corporation To Participate In A Securities Fraud Investigation

Aug 12, 2024, 8:00 PM EDT - 8 months ago

Investors Of Blueprint Medicines Corporation Are Informed By The Schall Law Firm About Ongoing Investigations Into Possible Securities Law Breaches

Aug 8, 2024, 8:30 PM EDT - 9 months ago

Market Cap	5.41B
Revenue (ttm)	508.82M
Net Income (ttm)	-67.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13.19%
Debt to Equity Ratio	1.30

Volume	634,400
Avg Vol	1,122,820
Day's Range	N/A - N/A
Shares Out	63.91M
Stochastic %K	98%
Beta	0.75
Analysts	Strong Sell
Price Target	$128.30